FDA Brief

Warning letters Drugs

FDA warning letter to

Sovereign Pharmaceuticals, LLC

High riskIssued Oct 5, 2022Posted Nov 1, 2022Office of Pharmaceutical Quality Operations, Division II

FDA cited Sovereign Pharmaceuticals for manufacturing failures in bulk tablets, inadequate out-of-specification (OOS) investigations, quality-unit lapses, and an unapproved biological product.

What happened

FDA inspected the Fort Worth facility from April 13 to 22, 2022 and found violations of current good manufacturing practice (CGMP). The agency found out-of-specification blend and tablet results during process validation, about 27 validation and commercial batches that failed blend powder drum assay and were compressed and released before adequate investigation, and quality-unit approval of validation reports with errors and omissions. FDA also found the drug listing did not name the firm as a manufacturer and that the firm was distributing a biological product without FDA approval or a valid biologics license.

What FDA found

  1. The company lacked adequate written production and process-control procedures and did not validate bulk tablet manufacturing; multiple out-of-specification blend and tablet results occurred during process performance qualification.

    21 CFR 211.100(a)
  2. The company did not thoroughly or timely investigate out-of-specification results; about 27 validation and commercial batches failed blend powder drum assay and were compressed and released before adequate investigation.

    21 CFR 211.192
  3. The quality unit did not properly follow its procedures or oversee quality; it approved validation reports that omitted drum assay failures and RSD calculations and did not investigate some stability chamber excursions.

    21 CFR 211.22(d)
  4. The company failed to list the drugs with FDA with the correct manufacturing establishment, making them misbranded.

    section 510 of the FD&C Act, 21 U.S.C. 360(j); 21 CFR 207.17 and 207.41; section 502(o), 21 U.S.C. 352(o)
  5. The company distributed a biological product without FDA approval or a valid biologics license.

What FDA wants

FDA asks Sovereign to correct the violations promptly and to respond in writing within 15 working days with corrective actions and the requested analyses, CAPA plans, assessments, and timelines; FDA also strongly recommends a CGMP consultant. If it cannot complete corrective actions in that time, it must state why and give a completion schedule.

Who should pay attention

  • companies that buy bulk tablets or finished drugs from Sovereign Pharmaceuticals
  • brands relying on Sovereign's validation or stability data
  • distributors or users of the unapproved biological product

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk